Japan Tissue Engineering Co., Ltd. (JP:7774)
:7774
Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥22.46B
Enterprise Value¥21.01B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.13
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.06
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet (Low Debt)A virtually debt-free capital structure materially lowers solvency risk and gives management durable flexibility to fund R&D, scale manufacturing, or absorb cash shortfalls. This structural buffer supports multi-quarter runway for strategy execution without near-term refinancing pressure.
Specialized Regenerative Medicine BusinessFocus on tissue-engineered regenerative therapies and proprietary cell-processing capabilities creates high technical and regulatory barriers to entry. Specialized manufacturing and clinical applications promote customer stickiness and long product life cycles, underpinning durable competitive advantage.
Diversified Revenue StreamsMultiple revenue pillars—product sales, contract manufacturing/services and collaboration milestones—diversify cash inflows. Contract and manufacturing services can smooth variability from product cycles and leverage fixed assets to improve throughput and margin sustainability over quarters.
Bears Say
Worsening Revenue & ProfitabilityTop-line declines and a sharp swing to a ¥-734.8M net loss in 2026 indicate the company is not yet achieving scale needed to cover fixed manufacturing and R&D costs. Persistent revenue contraction undermines long-term margin recovery and reduces internal ability to fund strategic growth.
Deteriorating Cash GenerationOperating cash flow and free cash flow turned sharply negative by 2026, increasing reliance on balance-sheet resources or external capital. Sustained cash burn constrains reinvestment in manufacturing scale-up and clinical programs, raising risk of dilution or delayed product commercialization.
Equity Erosion & Negative ReturnsEquity has declined as accumulated losses mount and ROE turned negative, meaning the balance sheet is being consumed to absorb operating losses. Persistent erosion of equity reduces the capital cushion and strategic flexibility, increasing solvency risk if losses continue.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥22.46B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is Aug 05, 2026 which is in 93 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on May 01, 2026. The company reported -¥4.39 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.39.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.39 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.34%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.